Savara Inc. (NASDAQ:SVRA) Given Average Recommendation of “Moderate Buy” by Brokerages

Savara Inc. (NASDAQ:SVRA) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $9.1250.

SVRA has been the subject of several recent analyst reports. William Blair set a $10.00 price objective on shares of Savara in a research note on Monday, March 16th. HC Wainwright reaffirmed a “buy” rating on shares of Savara in a report on Monday, March 16th. Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Oppenheimer began coverage on Savara in a report on Friday. They issued an “outperform” rating and a $11.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st.

Savara Trading Up 1.7%

Shares of Savara stock opened at $5.25 on Tuesday. The company has a quick ratio of 11.85, a current ratio of 11.85 and a debt-to-equity ratio of 0.15. The company’s 50-day simple moving average is $5.50 and its 200-day simple moving average is $5.38. Savara has a 52-week low of $1.89 and a 52-week high of $7.01. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -9.90 and a beta of 0.32.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Friday, March 13th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, equities research analysts anticipate that Savara will post -0.49 earnings per share for the current year.

Institutional Trading of Savara

Several institutional investors and hedge funds have recently modified their holdings of the business. Prudential Financial Inc. purchased a new position in shares of Savara during the 2nd quarter worth approximately $30,000. BNP Paribas Financial Markets increased its position in Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after buying an additional 4,626 shares in the last quarter. Brevan Howard Capital Management LP acquired a new position in shares of Savara in the second quarter worth $33,000. Russell Investments Group Ltd. lifted its position in shares of Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after acquiring an additional 9,463 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Savara during the third quarter valued at $44,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.